MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is broadening the scope of its AI-driven voice technology with the development of a fatigue prediction model designed for high-risk workplace environments. The company, which commercializes AI-powered voice analysis for drug and alcohol intoxication detection, plans to integrate the new capability into its Edge AI Intoxication Detection Kiosks, according to a recent article highlighting the expansion.
“The fatigue detection capability is expected to become an additional feature within MindBio’s planned Edge AI Intoxication Detection Kiosks, which are being designed to identify signs of alcohol, drug impairment and fatigue from short voice samples,” the publication reads. The announcement reflects a broader strategy by MindBio to position voice analytics as a scalable alternative to conventional impairment screening methods such as breathalyzers, saliva tests, urine analysis and laboratory-based toxicology testing.
Rather than relying on physical samples, the company’s platform analyzes speech characteristics captured through a microphone and processes the audio using machine learning models trained on large voice datasets. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
The expansion into fatigue detection is significant because it addresses a critical safety issue in high-risk workplaces where fatigue can impair judgment and reaction times, leading to accidents. According to the National Safety Council, fatigue-related incidents cost employers billions annually in lost productivity and liability. By adding fatigue prediction to its voice analytics platform, MindBio offers a non-invasive, real-time screening method that could replace or supplement traditional impairment tests.
For industries such as mining, aviation, and construction, where employee alertness is paramount, this technology could reduce accidents and improve safety compliance. The company’s kiosks are designed to be deployed at entry points, allowing employers to quickly assess workers before they begin their shifts. The voice-based approach eliminates the need for sample collection, reducing wait times and operational disruptions.
The implications for the broader industry are substantial. If successful, MindBio’s platform could set a new standard for impairment detection, moving away from reactive testing to proactive monitoring. The integration of fatigue detection also positions the company to tap into the growing market for workplace wellness and safety technology, which is projected to expand as regulators and employers prioritize mental and physical health.
For more information on MindBio Therapeutics, including the latest news and updates, visit the company’s newsroom at https://ibn.fm/MBQIF. The full article discussing the fatigue detection development is available at https://ibn.fm/UiSYI.
